Repros Therapeutics Inc. (NASDAQ:RPRX) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.

On July 17, 2017, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

Exhibit 99.1. Press release dated July 17, 2017

REPROS THERAPEUTICS INC. Exhibit
EX-99 2 exh_991.htm EXHIBIT 99.1 EdgarFilingEXHIBIT 99.1Repros Announces Proellex® Development Program Will Remain on Partial Clinical Hold by the FDA Repros Assessing Uterine Fibroid and Endometriosis Development Program with Vaginal Drug Delivery Treatment              Expects to Receive European Patent that Relates to Selective Progesterone Modulators THE WOODLANDS,…
To view the full exhibit click here

About Repros Therapeutics Inc. (NASDAQ:RPRX)

Repros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. The Company’s Proellex product candidate for female reproductive health is a chemical entity, which acts as a selective blocker of the progesterone receptor. It is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis The Company has an active Investigational New Drug (IND) for the vaginal delivery of Proellex for the treatment of uterine fibroids.